Peachtree Investment Partners, LLC Eli Lilly & CO Transaction History

Peachtree Investment Partners, LLC

$265 Million
Q3 2024

A detailed history of Peachtree Investment Partners, LLC transactions in Eli Lilly & CO stock. As of the latest transaction made, Peachtree Investment Partners, LLC holds 27,611 shares of LLY stock, worth $21.2 Million. This represents 9.22% of its overall portfolio holdings.

Number of Shares

27,611

Previous 27,808 0.71%

Holding current value

$21.2 Million

Previous $25.2 Million 2.84%

% of portfolio

9.22%

Previous 9.9%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$772.14 - $960.02 $152,111 - $189,123	-197 Reduced 0.71%	27,611 $24.5 Million
Q2 2024 Aug 12, 2024	BUY	$724.87 - $909.04 $31,169 - $39,088	43 Added 0.15%	27,808 $25.2 Million
Q1 2024 May 10, 2024	SELL	$592.2 - $792.28 $1.61 Million - $2.16 Million	-2,720 Reduced 8.92%	27,765 $21.6 Million
Q4 2023 Feb 12, 2024	SELL	$525.19 - $619.13 $471,620 - $555,978	-898 Reduced 2.86%	30,485 $17.8 Million
Q3 2023 Nov 13, 2023	BUY	$434.7 - $599.3 $2.68 Million - $3.7 Million	6,169 Added 24.47%	31,383 $16.9 Million
Q2 2023 Aug 14, 2023	BUY	$350.74 - $468.98 $5.01 Million - $6.71 Million	14,298 Added 130.98%	25,214 $11.8 Million
Q1 2023 May 15, 2023	SELL	$310.63 - $364.82 $2.14 Million - $2.51 Million	-6,887 Reduced 38.68%	10,916 $3.75 Million
Q4 2022 Feb 14, 2023	BUY	$321.55 - $374.67 $1.25 Million - $1.45 Million	3,883 Added 27.9%	17,803 $6.51 Million
Q3 2022 Nov 08, 2022	BUY	$296.48 - $337.87 $300,334 - $342,262	1,013 Added 7.85%	13,920 $4.5 Million
Q2 2022 Aug 16, 2022	BUY	$278.73 - $327.27 $1.84 Million - $2.16 Million	6,608 Added 104.91%	12,907 $4.19 Million
Q1 2022 Jun 08, 2022	SELL	$234.69 - $291.66 $47,407 - $58,915	-202 Reduced 3.11%	6,299 $1.8 Million
Q4 2021 Feb 11, 2022	BUY	$224.85 - $279.04 $293,204 - $363,868	1,304 Added 25.09%	6,501 $1.8 Million
Q3 2021 Nov 08, 2021	BUY	$221.6 - $272.71 $77,560 - $95,448	350 Added 7.22%	5,197 $1.2 Million
Q2 2021 Jul 27, 2021	SELL	$180.55 - $233.54 $39,540 - $51,145	-219 Reduced 4.32%	4,847 $1.11 Million
Q1 2021 May 05, 2021	BUY	$164.32 - $212.72 $71,807 - $92,958	437 Added 9.44%	5,066 $946,000
Q4 2020 Feb 16, 2021	BUY	$130.46 - $172.63 $3,913 - $5,178	30 Added 0.65%	4,629 $782,000
Q3 2020 Nov 03, 2020	BUY	$146.22 - $169.13 $672,465 - $777,828	4,599 New	4,599 $681,000
Q2 2020 Aug 13, 2020	SELL	$136.42 - $164.18 $615,254 - $740,451	-4,510 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$119.05 - $147.35 $34,881 - $43,173	-293 Reduced 6.1%	4,510 $625,000
Q4 2019 Feb 04, 2020	SELL	$106.92 - $132.43 $169,895 - $210,431	-1,589 Reduced 24.86%	4,803 $631,000
Q3 2019 Nov 14, 2019	SELL	$106.79 - $116.16 $234,938 - $255,552	-2,200 Reduced 25.61%	6,392 $715,000
Q2 2019 Jul 17, 2019	SELL	$110.79 - $129.32 $1.48 Million - $1.73 Million	-13,401 Reduced 60.93%	8,592 $952,000
Q1 2019 May 14, 2019	BUY	$111.31 - $131.02 $1.23 Million - $1.44 Million	11,026 Added 100.54%	21,993 $2.85 Million
Q4 2018 Feb 19, 2019	BUY	$105.9 - $118.64 $1.16 Million - $1.3 Million	10,967 New	10,967 $1.27 Million

Others Institutions Holding LLY

# of Institutions

4,011

Shares Held

751M

Call Options Held

8.27M

Put Options Held

10.5M

View Full List

About ELI LILLY & Co

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $730B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

More about LLY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Peachtree Investment Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Peachtree Investment Partners, LLC with notifications on news.

Account

Peachtree Investment Partners, LLC Eli Lilly & CO Transaction History